Company intelligence / Profile preview

ClearPath Bio

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

ClearPath Bio is a clinical-stage biotechnology company dedicated to developing precision medicines for oncology and other high-need therapeutic areas. The company's lead program, CPB-101, is a potent and selective small molecule inhibitor of the Menin-MLL (Mixed Lineage Leukemia) interaction, currently being evaluated for the treatment of acute leukemias. ClearPath Bio utilizes a partnership-centric model, often collaborating with larger pharmaceutical companies to accelerate the development of promising assets. The company is led by experienced industry veterans with a track record in drug development and corporate strategy.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Astellas Pharma

Beyond the preview

Go deeper on ClearPath Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ClearPath Bio.

Explore the full profile